Global cancer burden is transited and its pattern is changed throughout the world with different features in different geographical mappings.
The burden is rising up and the feature of cancers is transited from infection-related cancers such as cervical and stomach cancers to life style-related cancers such as prostate and breast cancers.
The risk factors are also changing; for example, smoking is declined in developed countries and rising up in developing countries (
35).
Here, we analyzed the data of national cancer registry from 2005 to 2014. Comparing to increasing the population rate, cancer cases are increasing rapidly (
Figure 1). As shown in
Figure 2 ASIR for both sexes is higher in male than female.
In
Figures 7 and
8, the distribution of total number of cancers during 10 years of study is higher for female population with 25 to 55 years and for males with 55 years and more.
Average population growth rate during 1991 to 2016
Breast cancer is the first cancer ranked in both sexes and also in females, although skin cancer, followed by stomach cancer, are two more incident cases in males in Iran (
Figure 7).
Increasing rate of cancer during the period of the study, are more related to age of people. Distribution of cancer in age 25 - 55 years is higher in females because of breast cancer and over 55 years in males because of gastrointestinal cancers (
Figure 7B).
Mortality due to cancer is rapidly decreased in both sexes (
Figure 2); in 2014, it is 61.85/10
5 in males and 39.55/10
5 in females compared to 96.77/10
5 and 65.75/10
5 in 2005, respectively.
Reason for differences of registration of cases in different years is transition of some cancers like stomach which is coming dawn in Tehran province from first to 3rd position and the second reason is unfavorable work on data registry in some provinces and more in some others.
The ischemic heart disease and stroke are separated and do not include CVDs. Because of the transition of cancer burden, in more than 40 developed countries, cancer-related deaths at age under 70 is equal or above CVDs (
36).
Assessment of cancer-specific mortality rate is an acceptable tool to evaluate secondary and tertiary prevention services (
37); that is to be able to determine the early detection and quality of care.
Cancer is more complicated compared with other NCDs, because of its natural biological status and heterogeneities, but at least its trend and indicators such as MIR will be represented as the management of cancer in each country.
Total fertility rate (TFR) is declined by 49.4% in the world from 1950 to 2017 (
38), and it has been 4.7 live births in 1950 and 2.4 live births in 2017.
In Iran, TFR is also declined through the last 40 years from 4.2 to 1.8 and because of that, the population growth rate is declined from 2.46 in 1991 to 1.24 in 2016 (
Figure 8) (
32).
During the last 30 years, the population younger than 14 years is declined from 45.5% to 24% and the population older than 65 years old is rising up from 5.5 in 1987 to 9.28 in 2017, and it is estimated to be 21% in 2051.
Although TFR is declined, the population is increased each year with the average of 83.8 million from 1985 to 2017 in the world (
38).
In Iran, the population is also increased from 40835000 in 1981 to 82377228 in 2019 (
32). In 2017, a little bit less than 10 million (955 6200 people) died due to cancer globally, which is 25.4% more than 2007. Age standardized death rate per 100 000 in 2017 was 121.2, which is declined by 4.4% compared to 2007and became 116.8 (
15).
Also, the YLL of neoplasms increased by 19.6% from 2007 to 2017 and reaches to 225738100 years, but age standardized YLL rate is declined by 5.6% compared to 2007 and reaches to 280 314 per 100 000 people.
Regarding increase in age standardized incidence rate of cancer cases, and decrease in the age standardized death rate, this feature is related to cancer in the world and it is similar to the features that you can see in Iran (
Figure 4).
Management of cancer in Iran is acceptable compared to the developed countries; so, it is good to mention some successful cancer management strategies in Iran:
a. Public awareness about requesting medical care.
b. Increasing accessibility and availability of medical care facility including man power.
c. Progressing team work for early diagnosis and better management through the country.
As Globocan estimated, the growth rate of cancer at next 20 years from 2020 to 2040 is noteworthy; this growth rate is 63.4% for world, 75.1% for Turkey (as a simple in the region), and 101.3% for west Asia, but it is 115.7% for Iran, which means the cancer cases in Iran will become at least twice more during next 20 years (
Figure 9) (
2).
Cancer incidence growth during 2020 to 2040 in west Asia and world
The estimation of population in Iran and Turkey at that time would be similar and both countries have around 93 to 95 million people, but incidence rate is dramatically higher in Iran (115.7% vs. 75.1%). Despite the growing of incidence rate during the study period, the mortality rate in Turkey and world is almost steady or little rising, but in Iran, it is decreasing rapidly (
Figure 10).
Comparison of ASMR during 2005 to 2014 (Iran, Turkey, World)
As it is reported by statistical center of Iran and also estimated by WHO (
Figure 11), the rate of population older than 60 years in Iran is less than 10% (9.28% - 9.8%), but during 2020, it is ≤ 20% and in the next 10 years, it would be ≤ 30% and after the next 20 years (during 2050), it will be 30% or more, but for Turkey, it is more stable and remained less than 10% until 2050 (
2).
Population is getting older in the world and Iran (> 30%)
The TFR and life expectancy are more important issues; population is getting older and it is the most powerful reason for increasing cancer cases in Iran (
Figure 12) (
38).
Rate of aged people (≥ 60 Years old) in Iran during the next 20 years
Also in the
Figure 1, the trend of population and cancer incidence during 10 years of study are not compatible and the incidence rate of cancer changed from 75 to 141 per 100000.
The trend of ASMR to ASIR, which is called MIR, is very interesting during 10 years of study from 2005 to 2014 (
Figure 5).
It is changed from 0.79% to 0.32%, meaning that nowadays more than 70% of cancer cases will survive each year, and it is a good tool for the assessment of secondary and tertiary prevention of cancer in Iran (
39).
5.1. Conclusions
The population of Iran is steadily increasing, which is in line with the increase worldwide, but the rate of aged people is increasing rapidly and because of this, the incidence rate of cancer is rising up; however, the mortality rate is going down with increasing cancer burden.
The assessment of cancer management in Iran is acceptable compared to the developed countries.